Literature DB >> 19133241

Increased leukocyte ROCK activity in patients after acute ischemic stroke.

Steven K Feske1, Farzaneh A Sorond, Galen V Henderson, Minoru Seto, Asako Hitomi, Koh Kawasaki, Yasuo Sasaki, Toshio Asano, James K Liao.   

Abstract

BACKGROUND: Rho-kinase (ROCK) is a downstream effector of Rho GTPase that is known to regulate various pathological processes important to the development of ischemic stroke, such as thrombus formation, inflammation, and vasospasm. Inhibition of ROCK leads to decreased infarct size in animal models of ischemic stroke. This study tests the hypothesis that ROCK activity increases during the acute phase of ischemic stroke.
METHODS: Serial blood samples were drawn from 10 patients with acute ischemic stroke presenting within 24 h of symptom onset and with NIHSS scores >or=4. Samples were taken at 24, 48, and 72 h. Leukocyte ROCK activity was determined by immunoblotting leukocyte lysates with antibodies to the phosphorylated form of myosin-binding subunit (P-MBS) of myosin light chain phosphatase (MLCP). MBS and P-MBS contents were normalized to alpha-tubulin, and ROCK activity was expressed as the ratio of P-MBS to MBS. ROCK activities in these 10 patients were compared to baseline ROCK activities in 10 control subjects without acute illness and matched for sex, age, and number of vascular risk factors using a two-tailed Student's t-test.
RESULTS: The mean NIHSS score in patients with stroke was 15.4. ROCK activity was significantly increased at 24 and 48 h in patients after acute ischemic stroke when compared to control values, with peak elevations at 48 h after stroke onset. There was no apparent correlation between ROCK activity and stroke severity based on NIHSS.
CONCLUSIONS: Leukocyte ROCK activity is increased in patients after acute ischemic stroke with maximal activity occurring about 48 h after stroke onset. These findings suggest that activation of ROCK may play a role in the pathogenesis of ischemic stroke in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19133241      PMCID: PMC2646801          DOI: 10.1016/j.brainres.2008.12.045

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  36 in total

1.  Endothelin-1-induced vasospasms of spiral modiolar artery are mediated by rho-kinase-induced Ca(2+) sensitization of contractile apparatus and reversed by calcitonin gene-related Peptide.

Authors:  Elias Q Scherer; Michael Herzog; Philine Wangemann
Journal:  Stroke       Date:  2002-12       Impact factor: 7.914

2.  Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans.

Authors:  A Masumoto; Y Hirooka; H Shimokawa; K Hironaga; S Setoguchi; A Takeshita
Journal:  Hypertension       Date:  2001-12-01       Impact factor: 10.190

3.  Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats.

Authors:  Chu Kataoka; Kensuke Egashira; Shujiro Inoue; Masao Takemoto; Weihua Ni; Masamichi Koyanagi; Shiro Kitamoto; Makoto Usui; Kozo Kaibuchi; Hiroaki Shimokawa; Akira Takeshita
Journal:  Hypertension       Date:  2002-02       Impact factor: 10.190

4.  Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina.

Authors:  Akihiro Masumoto; Masahiro Mohri; Hiroaki Shimokawa; Lemmy Urakami; Makoto Usui; Akira Takeshita
Journal:  Circulation       Date:  2002-04-02       Impact factor: 29.690

5.  Reduction of hepatic ischemia/reperfusion-induced injury by a specific ROCK/Rho kinase inhibitor Y-27632.

Authors:  Fusao Ikeda; Hiroaki Terajima; Yasuyuki Shimahara; Tadashi Kondo; Yoshio Yamaoka
Journal:  J Surg Res       Date:  2003-02       Impact factor: 2.192

6.  Rho/Rho-kinase pathway in the brainstem contributes to hypertension caused by chronic nitric oxide synthase inhibition.

Authors:  Koji Ito; Yoshitaka Hirooka; Takuya Kishi; Yoshikuni Kimura; Kozo Kaibuchi; Hiroaki Shimokawa; Akira Takeshita
Journal:  Hypertension       Date:  2004-01-19       Impact factor: 10.190

7.  Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase.

Authors:  Masao Takemoto; Jianxin Sun; Junko Hiroki; Hiroaki Shimokawa; James K Liao
Journal:  Circulation       Date:  2002-07-02       Impact factor: 29.690

8.  Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury.

Authors:  Weike Bao; Erding Hu; Ling Tao; Rogely Boyce; Rosanna Mirabile; Douglas T Thudium; Xin-ling Ma; Robert N Willette; Tian-li Yue
Journal:  Cardiovasc Res       Date:  2004-02-15       Impact factor: 10.787

9.  Rho/Rho-kinase pathway in brain stem contributes to blood pressure regulation via sympathetic nervous system: possible involvement in neural mechanisms of hypertension.

Authors:  Koji Ito; Yoshitaka Hirooka; Koji Sakai; Takuya Kishi; Kozo Kaibuchi; Hiroaki Shimokawa; Akira Takeshita
Journal:  Circ Res       Date:  2003-06-05       Impact factor: 17.367

10.  Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice.

Authors:  Ziad Mallat; Andrea Gojova; Vincent Sauzeau; Valérie Brun; Jean-Sébastien Silvestre; Bruno Esposito; Régine Merval; Hervé Groux; Gervaise Loirand; Alain Tedgui
Journal:  Circ Res       Date:  2003-10-02       Impact factor: 17.367

View more
  17 in total

1.  Measurement of Rho-associated kinase (ROCK) activity in humans: validity of leukocyte p-MBS/t-MBS in comparison with vascular response to fasudil.

Authors:  Takaki Hata; Chikara Goto; Junko Soga; Takayuki Hidaka; Yuichi Fujii; Naomi Idei; Noritaka Fujimura; Tatsuya Maruhashi; Shinsuke Mikami; Yasuki Kihara; Kazuaki Chayama; Kensuke Noma; James K Liao; Yukihito Higashi
Journal:  Atherosclerosis       Date:  2010-10-12       Impact factor: 5.162

2.  Gene variations of ROCKs and risk of ischaemic stroke: the Women's Genome Health Study.

Authors:  Robert Y L Zee; Qing-Mei Wang; Daniel I Chasman; Paul M Ridker; James K Liao
Journal:  Clin Sci (Lond)       Date:  2014-06       Impact factor: 6.124

3.  Neuroprotection Mediated by Upregulation of Endothelial Nitric Oxide Synthase in Rho-Associated, Coiled-Coil-Containing Kinase 2 Deficient Mice.

Authors:  Yukio Hiroi; Kensuke Noma; Hyung-Hwan Kim; Nikola Sladojevic; Corey E Tabit; Yuxin Li; Guray Soydan; Salvatore Salomone; Michael A Moskowitz; James K Liao
Journal:  Circ J       Date:  2018-01-19       Impact factor: 2.993

4.  A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction.

Authors:  Carolyn Hoppe; Frans Kuypers; Sandra Larkin; Ward Hagar; Elliott Vichinsky; Lori Styles
Journal:  Br J Haematol       Date:  2011-04-08       Impact factor: 6.998

Review 5.  Peripheral polymorphonuclear leukocyte activation as a systemic inflammatory response in ischemic stroke.

Authors:  Xiaoye Mo; Ting Li; Guang Ji; Wei Lu; Zhiping Hu
Journal:  Neurol Sci       Date:  2013-04-26       Impact factor: 3.307

Review 6.  ROCKs as immunomodulators of stroke.

Authors:  Qing Mei Wang; James K Liao
Journal:  Expert Opin Ther Targets       Date:  2012-08-27       Impact factor: 6.902

7.  A combination of increased Rho kinase activity and N-terminal pro-B-type natriuretic peptide predicts worse cardiovascular outcome in patients with acute coronary syndrome.

Authors:  Ming Dong; James K Liao; Bryan Yan; Ruijie Li; Mang Zhang; Cheuk-Man Yu
Journal:  Int J Cardiol       Date:  2012-08-24       Impact factor: 4.164

8.  Elevated rho-kinase activity as a marker indicating atherosclerosis and inflammation burden in polyvascular disease patients with concomitant coronary and peripheral arterial disease.

Authors:  Ming Dong; Xin Jiang; James K Liao; Bryan P Yan
Journal:  Clin Cardiol       Date:  2013-03-28       Impact factor: 2.882

Review 9.  ROCK as a therapeutic target for ischemic stroke.

Authors:  Nikola Sladojevic; Brian Yu; James K Liao
Journal:  Expert Rev Neurother       Date:  2017-10-30       Impact factor: 4.618

10.  Rho-associated kinase activity is a predictor of cardiovascular outcomes.

Authors:  Masato Kajikawa; Kensuke Noma; Tatsuya Maruhashi; Shinsuke Mikami; Yumiko Iwamoto; Akimichi Iwamoto; Takeshi Matsumoto; Takayuki Hidaka; Yasuki Kihara; Kazuaki Chayama; Ayumu Nakashima; Chikara Goto; James K Liao; Yukihito Higashi
Journal:  Hypertension       Date:  2013-12-30       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.